702 related articles for article (PubMed ID: 18779710)
1. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
4. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.
Iturralde D; Spaide RF; Meyerle CB; Klancnik JM; Yannuzzi LA; Fisher YL; Sorenson J; Slakter JS; Freund KB; Cooney M; Fine HF
Retina; 2006 Mar; 26(3):279-84. PubMed ID: 16508427
[TBL] [Abstract][Full Text] [Related]
8. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone.
Larsson J; Zhu M; Sutter F; Gillies MC
Am J Ophthalmol; 2005 May; 139(5):802-6. PubMed ID: 15860283
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone for refractory diabetic macular edema.
Martidis A; Duker JS; Greenberg PB; Rogers AH; Puliafito CA; Reichel E; Baumal C
Ophthalmology; 2002 May; 109(5):920-7. PubMed ID: 11986098
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema.
Micelli Ferrari T; Sborgia L; Furino C; Cardascia N; Ferreri P; Besozzi G; Sborgia C
Eur J Ophthalmol; 2004; 14(4):321-4. PubMed ID: 15309977
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal triamcinolone acetonide as primary treatment for diffuse diabetic macular edema: a prospective noncomparative interventional case series.
Nicolò M; Nasciuti F; Lai S; Ghiglione D; Borgia L; Calabria G
Eur J Ophthalmol; 2006; 16(1):129-33. PubMed ID: 16496256
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders.
Tewari HK; Sony P; Chawla R; Garg SP; Venkatesh P
Eur J Ophthalmol; 2005; 15(5):619-26. PubMed ID: 16167293
[TBL] [Abstract][Full Text] [Related]
13. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion.
Rosenfeld PJ; Fung AE; Puliafito CA
Ophthalmic Surg Lasers Imaging; 2005; 36(4):336-9. PubMed ID: 16156153
[TBL] [Abstract][Full Text] [Related]
14. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
[TBL] [Abstract][Full Text] [Related]
15. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema.
Jonas JB; Martus P; Degenring RF; Kreissig I; Akkoyun I
Arch Ophthalmol; 2005 Oct; 123(10):1338-43. PubMed ID: 16219724
[TBL] [Abstract][Full Text] [Related]
17. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema.
Yamamoto T; Hitani K; Tsukahara I; Yamamoto S; Kawasaki R; Yamashita H; Takeuchi S
Am J Ophthalmol; 2003 Jan; 135(1):14-9. PubMed ID: 12504691
[TBL] [Abstract][Full Text] [Related]
18. Factors predicting outcome of vitrectomy for diabetic macular oedema: results of a prospective study.
Shah SP; Patel M; Thomas D; Aldington S; Laidlaw DA
Br J Ophthalmol; 2006 Jan; 90(1):33-6. PubMed ID: 16361663
[TBL] [Abstract][Full Text] [Related]
19. [Intravitreal triamcinolone acetonide for diffuse diabetic macular edema--one year follow-up].
Thein R; Pollack A; Bukelman A; Katz H; Pokroy R; Len A; Parnes R; Aloni E; Hauser D
Harefuah; 2005 Nov; 144(11):759-62, 824. PubMed ID: 16358647
[TBL] [Abstract][Full Text] [Related]
20. The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series.
Javadzadeh A
BMC Ophthalmol; 2006 Apr; 6():15. PubMed ID: 16595011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
